Results 1 to 10 of about 67,365 (299)
Equine glucagon-like peptide-1 receptor physiology [PDF]
PeerJ, 2018 Background Equine metabolic syndrome (EMS) is associated with insulin dysregulation, which often manifests as post-prandial hyperinsulinemia. Circulating concentrations of the incretin hormone, glucagon-like peptide-1 (GLP-1) correlate with an increased ...
Murad H. Kheder +4 more
doaj +5 more sources
Glucagon-like peptide-1 receptor agonists in orthopaedics [PDF]
SICOT-JGlucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA) help people control blood glucose and lose weight. They may also help with bone metabolism, healing fractures, keeping joints healthy, and recovering after surgery.
Mavrogenis Andreas F. +7 more
doaj +2 more sources
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes [PDF]
Annals of Pediatric Endocrinology & Metabolism, 2017 The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from various diabetes-related complications. Since there are many patients with T2D that cannot be controlled by previously developed drugs, it has been necessary ...
Seungah Lee, Dong Yun Lee
doaj +3 more sources
Signaling architecture of the glucagon-like peptide-1 receptor. [PDF]
J Clin InvestThe glucagon-like peptide-1 receptor (GLP-1R) is a class B1 G protein-coupled receptor and major therapeutic target in type 2 diabetes and obesity. Beyond its canonical role in Gαs/cAMP signaling, GLP-1R is increasingly recognized as an organizer of spatiotemporally defined signaling nanodomains, or "signalosomes." This Review highlights our current ...
Austin G, Tomas A.
europepmc +3 more sources
Effects of Treatment with Glucagon-like Peptide-1 Receptor Analogues on the Diabetic Foot [PDF]
BiomedicinesBackground/Objectives: Diabetic foot disease is one of the most severe and disabling complications of type 2 diabetes mellitus, resulting from the interaction between peripheral neuropathy, peripheral arterial disease, and infection.
Mercedes Ortiz Romero +3 more
doaj +2 more sources
Dermatological Manifestations of Glucagon‐Like Peptide‐1 Receptor Agonists [PDF]
JEADV Clinical PracticeBackground Glucagon‐like peptide‐1 receptor agonists (GLP‑1 RAs) play a pivotal role in treating type 2 diabetes. Despite their widespread use, their dermatological manifestations remain under‐recognized, hence the interest of this systematic review ...
Nour Ghostine, Maya Halabi‐Tawil
doaj +2 more sources
Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Arrhythmias [PDF]
Journal of ArrhythmiaBackground Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), initially designed to treat diabetes mellitus (DM), have demonstrated the potential to mitigate obesity‐related cardiovascular risks.
Vikash Jaiswal +12 more
doaj +2 more sources
Glucagon-like peptide-1 receptor agonists in neoplastic diseases
Frontiers in EndocrinologyGlucagon-like peptide-1 receptor agonist (GLP-1RA), a novel hypoglycemic agent for the treatment of type 2 diabetes, has well-known effects such as lowering blood sugar, ameliorating inflammation, reducing weight, and lowering blood lipids.
Lisan Ji +8 more
doaj +3 more sources
History of glucagon-like peptide-1 receptor agonists
Pharmacological ResearchRadwan Darwish +2 more
doaj +3 more sources
Frontiers in Endocrinology, 2021 ObjectiveNon-alcoholic fatty liver disease is highly prevalent in patients with type 2 diabetes mellitus. Studies on glucagon-like peptide-1 receptor agonists for the treatment of non-alcoholic fatty liver disease have reported promising results. Despite
Chloe Wong +12 more
doaj +1 more source